Breast cancer
Top Cited Papers
Open Access
- 16 November 2016
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 389 (10074), 1134-1150
- https://doi.org/10.1016/s0140-6736(16)31891-8
Abstract
No abstract availableKeywords
This publication has 168 references indexed in Scilit:
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Breast-Cancer Adjuvant Therapy with Zoledronic AcidThe New England Journal of Medicine, 2011
- Adjuvant Trastuzumab in HER2-Positive Breast CancerThe New England Journal of Medicine, 2011
- The treatment of early breast cancer in women over the age of 70British Journal of Cancer, 2011
- Effect of Occult Metastases on Survival in Node-Negative Breast CancerThe New England Journal of Medicine, 2011
- Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Adjuvant Chemotherapy in Older Women with Early-Stage Breast CancerThe New England Journal of Medicine, 2009